It’s all in for the HER family in tumorigenesis

References

• Prickett TD, Agrawal NS, Wei X et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet.41(10), 1127–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer9(7), 463–475 (2009).
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol.21(2), 177–184 (2009).
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol.7(7), 505–516 (2006).
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer5(5), 341–354 (2005).
   PubMed Web of Science ®Google Scholar
• Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck25(1), 67–73 (2003).
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl Acad. Sci. USA89(10), 4309–4313 (1992).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676), 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244(4905), 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Williams TM, Weiner DB, Greene MI, Maguire HC Jr. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology59(1), 46–52 (1991).
   PubMed Web of Science ®Google Scholar
• Schneider PM, Hung MC, Chiocca SM et al. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res.49(18), 4968–4971 (1989).
   PubMed Web of Science ®Google Scholar
• Ibrahim SO, Vasstrand EN, Liavaag PG, Johannessen AC, Lillehaug JR. Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res.17(6D), 4539–4546 (1997).
   PubMed Web of Science ®Google Scholar
• Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp. Cell. Res.284(1), 99–110 (2003).
   PubMed Web of Science ®Google Scholar
• Bobrow LG, Millis RR, Happerfield LC, Gullick WJ. c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur. J. Cancer33(11), 1846–1850 (1997).
   PubMed Web of Science ®Google Scholar
• Quinn CM, Ostrowski JL, Lane SA, Loney DP, Teasdale J, Benson FA. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology25(3), 247–252 (1994).
   PubMed Web of Science ®Google Scholar
• Travis A, Pinder SE, Robertson JF et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br. J. Cancer74(2), 229–233 (1996).
   PubMed Web of Science ®Google Scholar
• Rajkumar T, Stamp GW, Hughes CM, Gullick WJ. c-erbB3 protein expression in ovarian cancer. Clin. Mol. Pathol.49(4), M199–M202 (1996).
   Google Scholar
• Tanner B, Hasenclever D, Stern K et al. ErbB-3 predicts survival in ovarian cancer. J. Clin. Oncol.24(26), 4317–4323 (2006).
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA, Mermel C et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA102(10), 3788–3793 (2005).
   PubMed Web of Science ®Google Scholar
• Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res.6(11), 4217–4225 (2000).
   PubMed Web of Science ®Google Scholar
• Suo Z, Risberg B, Kalsson MG et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J. Pathol.196(1), 17–25 (2002).
   PubMed Web of Science ®Google Scholar
• Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. J. Pathol.200(3), 290–297 (2003).
   PubMed Web of Science ®Google Scholar
• Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin. Cancer Res.11(6), 2163–2168 (2005).
   PubMed Web of Science ®Google Scholar
• Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RC, Angus B. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J. Clin. Pathol.56(4), 300–304 (2003).
   PubMed Web of Science ®Google Scholar
• Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int. J. Cancer106(5), 758–765 (2003).
   PubMed Web of Science ®Google Scholar
• Peles E, Bacus SS, Koski RA et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell69(1), 205–216 (1992).
   PubMed Web of Science ®Google Scholar
• Bacus SS, Gudkov AV, Zelnick CR et al. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res.53(21), 5251–5261 (1993).
   PubMed Web of Science ®Google Scholar
• Bacus SS, Huberman E, Chin D et al. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ.3(7), 401–411 (1992).
   PubMedGoogle Scholar
• Culouscou JM, Plowman GD, Carlton GW, Green JM, Shoyab M. Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor. J. Biol. Chem.268(25), 18407–18410 (1993).
   PubMed Web of Science ®Google Scholar
• Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res.57(17), 3804–3811 (1997).
   PubMed Web of Science ®Google Scholar
• Sartor CI, Zhou H, Kozlowska E et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol. Cell Biol.21(13), 4265–4275 (2001).
   PubMed Web of Science ®Google Scholar
• Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.Cancer Res.59(20), 5315–5322 (1999).
   PubMed Web of Science ®Google Scholar
• Alaoui-Jamali MA, Song DJ, Benlimame N et al. Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer Res.63(13), 3764–3774 (2003).
   PubMed Web of Science ®Google Scholar
• Maatta JA, Sundvall M, Junttila TT et al. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol. Biol. Cell17(1), 67–79 (2006).
   PubMed Web of Science ®Google Scholar
• Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene18(16), 2607–2615 (1999).
   PubMed Web of Science ®Google Scholar
• Elenius K, Corfas G, Paul S et al. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J. Biol. Chem.272(42), 26761–26768 (1997).
   PubMed Web of Science ®Google Scholar
• Junttila TT, Sundvall M, Maatta JA, Elenius K. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc. Med.10(7), 304–310 (2000).
   PubMed Web of Science ®Google Scholar
• Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene21(41), 6255–6263 (2002).
   PubMed Web of Science ®Google Scholar
• Rusnak DW, Lackey K, Affleck K et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.. Mol. Cancer Ther.1(2), 85–94 (2001).
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab. Nature421(6924), 756–760 (2003).
   PubMed Web of Science ®Google Scholar
• Longva KE, Pedersen NM, Haslekas C, Stang E, Madshus IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer116(3), 359–367 (2005).
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell6(2), 117–127 (2004).
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med.6(4), 443–446 (2000).
   PubMed Web of Science ®Google Scholar
• Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol.26(11), 1789–1796 (2008).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol.23(19), 4265–4274 (2005).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med.354(8), 809–820 (2006).
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet369(9555), 29–36 (2007).
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res.14(10), 2895–2899 (2008).
   PubMed Web of Science ®Google Scholar
• Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res.68(5), 1471–1477 (2008).
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer108(3), 334–341 (2004).
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl Cancer Inst.93(24), 1852–1857 (2001).
   PubMed Web of Science ®Google Scholar
• Buck E, Eyzaguirre A, Rosenfeld-Franklin M et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res.68(20), 8322–8332 (2008).
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science316(5827), 1039–1043 (2007).
   PubMed Web of Science ®Google Scholar
• Sergina NV, Rausch M, Wang D et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature445(7126), 437–441 (2007).
   PubMed Web of Science ®Google Scholar
• Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res.67(4), 1842–1852 (2007).
   PubMed Web of Science ®Google Scholar